Stopsack KH, et al. - Researchers used a prospective cohort to verify whether there is an association between aspirin use and a lower risk of the common prostate cancer molecular subtype (the TMPRSS2:ERG gene fusion). A total of 49,395 men who reported on aspirin use in biennial questionnaires in the Health Professionals Follow-up Study were followed for prostate cancer incidence over 23 years. Using immunohistochemistry, evaluation of TMPRSS2:ERG status was done for presence of ERG on archival tumor specimens for 912 prostate cancer patients; 48% of these were ERG-positive. Findings did not support the hypothesis that aspirin use is associated with a lower risk of ERG-positive prostate cancer.